Get in touch

Avidity analytics for immunotherapy development

Avigen is a preclinical Contract Research Organisation offering cell and biologics avidity analysis services. We enable you to identify your most potent immunotherapy — before you commit to costly in vivo studies.

Preclinical Contract Research Organisation

Accelerate your immunotherapy
breakthroughs with Avigen

technologyA new dimension in immunotherapy R&D

Our platform redefines how potent immune cells are identified—measuring cellular avidity to uncover what truly drives therapeutic success.

Physiological Relevance

Captures the full complexity of live immune–target cell interactions, delivering insights that better reflect in-vivo therapeutic behaviour.

High Throughput

Analyses tens of thousands of single-cell interactions per run—and scales to millions, enabling comprehensive profiling of diverse immune cell populations.

Gentle

Maintains cell viability and functionality for immediate downstream testing, seamlessly integrating into your existing R&D pipeline.

Fully Adaptable

Compatible with a wide range of adherent target cells and immune cell types, including TCR-T, CAR-T, NK, and beyond—across various solid tumour indications.

servicesPreclinical avidity services for every stage of your programme

From initial lead identification through to pre-IND candidate confirmation, our platform adds a layer of translational insight that standard assays cannot provide — helping you advance the right candidates with confidence.
financial-information

Immunotherapy validation

Completing the immune cell data set and ranking candidates for confident translation.

Cell

Immunotherapy discovery

Identifying target-specific leads amongst millions of potential candidates.

Contact us to explore how we can help you develop your next therapy

technologyA new dimension in
immunotherapy R&D

Our platform redefines how potent immune cells are identified—measuring cellular avidity to uncover what truly drives therapeutic success.

Physiological Relevance

Captures the full complexity of live immune–target cell interactions, delivering insights that better reflect in-vivo therapeutic behaviour.

High Throughput

Analyses tens of thousands of single-cell interactions per run—and scales to millions, enabling comprehensive profiling of diverse immune cell populations.

Gentle

Maintains cell viability and functionality for immediate downstream testing, seamlessly integrating into your existing R&D pipeline.

Fully Adaptable

Compatible with a wide range of adherent target cells and immune cell types, including TCR-T, CAR-T, NK, and beyond—across various solid tumour indications.

Immunotherapy validation

Completing the immune cell data set and ranking candidates for confident translation.

Immunotherapy discovery

Identifying target-specific leads amongst millions of potential candidates.

Contact us to explore how we can help you develop your next therapy

testimonialsTrusted by scientists developing
the next generation of therapies

testimonialsHear what our customers say about us

partnersOur partners

explore what we doFeatured news